Clinical Characteristics of Malignant Phosphaturic Mesenchymal Tumor Causing Tumor-Induced Osteomalacia
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgad690 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Veronica Abate und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy. Hauptthemen laut MEDLINE: Osteomalacia, Neoplasms, Connective Tissue, Paraneoplastic Syndromes, Soft Tissue Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Context
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome usually caused by oversecretion of fibroblast growth factor 23 (FGF23) from a phosphaturic mesenchymal tumor (PMT). PMTs are usually benign neoplasms but some of them show malignant characteristics.
Objective
The aim of this study was to compare the clinical characteristics of benign and malignant PMTs inducing TIO.
Methods
On March 31, 2023, we performed a systematic review of individual patient data analysis in Medline, Google Scholar, Google book, and Cochrane Library using the terms “tumor induced osteomalacia,” “oncogenic osteomalacia,” “hypophosphatemia,” with no language restrictions and according to Preferred Reporting Items for Systematic reviews and Meta-Analyses criteria.
Results
Overall, we collected data from 837 patients with TIO in which the diagnosis of benign and malignant PMT was specified. Of them, 89 were affected by malignant PMT and 748 by benign PMT. Patients with malignant PMTs were younger and presented bone pain, functional impairment, and bone deformities more frequently. Malignant PMTs showed higher values of intact FGF23 and a higher mortality rate.
Conclusion
The study results identify the clinical characteristics of patients with malignant TIO, permitting the early identification of patients with PMT at increased risk of malignancy. This may significantly improve the diagnostic approach to disease. Further experimental studies are mandatory to clarify the role of FGF23 in the pathogenesis of malignancy in PMTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.
- Assistance Publique-Hôpitaux de Paris, Hôpital Robert-Debré, Service d'Endocrinologie-Diabétologie, 75019 Paris, France.
- Clinical Department of Oncology and Hematology, University of Naples "Federico II", 80131 Naples, Italy.
ORCID-Profile: Veronica Abate, Anita Vergatti, Gianpaolo De Filippo, Lanfranco D'Elia, Domenico Rendina
Zitieren
APA
Abate, V., Vergatti, A., De Filippo, G., Damiano, V., Menale, C., D'Elia, L., & Rendina, D. (2024). Clinical Characteristics of Malignant Phosphaturic Mesenchymal Tumor Causing Tumor-Induced Osteomalacia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad690
Vancouver
Abate V, Vergatti A, De Filippo G, Damiano V, Menale C, D'Elia L, et al. Clinical Characteristics of Malignant Phosphaturic Mesenchymal Tumor Causing Tumor-Induced Osteomalacia. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad690
BibTeX
@article{Abate2024,
author = {Abate, Veronica and Vergatti, Anita and De Filippo, Gianpaolo and Damiano, Vincenzo and Menale, Ciro and D'Elia, Lanfranco and Rendina, Domenico},
title = {Clinical Characteristics of Malignant Phosphaturic Mesenchymal Tumor Causing Tumor-Induced Osteomalacia},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgad690}
}
EUVIMED